
BIOPHEN™ FVIII Variant — Emicizumab-Insensitive FVIII Assay (Bovine FX)
Price:
$461.00
Product DescriptionFor Research Use Only. Not for Use in Diagnostic Procedures. Chromogenic assay for Factor VIII activity using bovine Factor X (FX) reagents — specifically designed to be insensitive to Emicizumab (Hemlibra®). CE-IVD. When patients on Emicizumab require accurate measurement of their endogenous or infused FVIII separately from Emicizumab activity, this bovine-FX design is required. The human-FX based BIOPHEN™ FVIII:C detects Emicizumab; this variant does not.
Product Characteristics
Product Components |
Product Applications
Chromogenic method for the in vitro quantitative determination of Factor VIII (FVIII) activity, in human citrated plasma or FVIII concentrates, using an automated method.
This method is for the detection of FVIII deficiency states and monitoring of replacement therapy (except Emicizumab) on patients who are suspected of congenital or acquired deficiency and potency estimation of FVIII concentrates. This device of in vitro diagnostic use is intended for professional use in the laboratory.
|